SCHEMBL3841687

SCHEMBL3841687

N#Cc1cc(-c2ccncc2)c(-c2ccc(F)cc2)nc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 1/20 0.47
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
MAPK14 Q16539 7/20 0.45
BRAF P15056 1/20 0.44
KDR P35968 1/20 0.44
GCGR P47871 2/20 0.44
MAPK13 O15264 2/20 0.44
MAPK12 P53778 2/20 0.44
MAPK11 Q15759 2/20 0.44
ALOX5 P09917 1/20 0.44
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
MAPK10 P53779 1/20 0.43
ADORA2B P29275 1/20 0.43
CHUK O15111 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6765596 0.87 ADORA1 (0.49) KDM4EALDH1A1GAAHPGDMAPK14
SCHEMBL2930455 0.85 SQOR (0.48) SQORKDM4EALDH1A1HPGDMAPK14
SCHEMBL2932218 0.84 CNR1 (0.49) SQORMAPK14BRAFKDRGCGR
SCHEMBL3841682 0.82 ADORA2A (0.46) KDM4EALDH1A1GAAHPGDMAPK14
SCHEMBL4905633 0.78 ALDH1A1 (0.51) KDM4EALDH1A1GAAHPGDADORA2A
SCHEMBL6765561 0.77 ALDH1A1 (0.59) KDM4EALDH1A1GAAHPGDADORA2A
SCHEMBL22163939 0.77 TGFBR1 (0.43) KDM4EALDH1A1GAAHPGDMAPK14
SCHEMBL3058808 0.76 MAPK14 (0.65) MAPK14GCGRMAPK13MAPK12MAPK11
SCHEMBL20657816 0.76 ADORA2A (0.44) KDM4EALDH1A1GAAHPGDADORA2A
SCHEMBL29409515 0.76 PDE3B (0.51) KDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1308441-B1 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS EISAI R&D MAN CO LTD (JP) 2009-10-07 EP disclosed
US-6750232-B2 ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS EISAI CO., LTD. (JP) 2004-06-15 US disclosed
US-20040006082-A1 2-Aminopyridine compounds and use thereof as drugs EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-01-08 US disclosed
EP-1308441-A1 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS Eisai Co., Ltd. (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006082-A1 2-Aminopyridine compounds and use thereof as drugs ADORA1, ADORA2B, ADORA2A SQOR 2989/4885KDM4E 768/4885ALDH1A1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.